Comprehensive analyses of m1A regulator-mediated modification patterns determining prognosis in lower-grade glioma (running title: m1A in LGG)

• DOI: 10.1016/j.heliyon.2024.e27510
• Publication Date: 2024-03-07T08:46:00Z
• Authors: Kunjian Lei; Yilei Sheng; Min Luo; Junzhe Liu; Chuandong Gong; Shigang Lv; Wei Tu; Minhua Ye; Miaojing Wu; Bing xiao; Hua Fang; Haitao Luo; Xinjun Liu; Xiaoyan Long; Xingen Zhu; Kai Huang; Jingying Li
• Keywords: N1-methyladenosine; Social sciences (General); H1-99; 0301 basic medicine; Q1-390; 03 medical and health sciences; Science (General); Prognostic signature; ssGSEA; Lower-grade glioma; Tumor immune; Research Article

N1-methyladenosine (m1A) modification is a crucial post-transcriptional regulatory mechanism of messenger RNA (mRNA) in living organisms. Few studies have focused on analysis of m1A regulators in lower-grade gliomas (LGG). We employed the Nonnegative Matrix Factorization (NMF) technique on The Cancer Genome Atlas (TCGA) dataset to categorize LGG patients into 2 groups. These groups exhibited substantial disparities in terms of both overall survival (OS) and levels of infiltrating immune cells. We collected the significantly differentially expressed immune-related genes between the 2 clusters, and performed LASSO regression analysis to obtain m1AScores, and established an m1A-related immune-related gene signature (m1A-RIGS). Next, we categorized all patients with LGG into high- and low-risk subgroups, predictive significance of m1AScore was confirmed by conducting univariate/multivariate Cox regression analyses. Additionally, we confirmed variations in immune-related cells and ssGSEA and among the high-/low-risk subcategories in the TCGA dataset. Finally, our study characterized the effects of MSR1 and BIRC5 on LGG cells utilizing Edu assay and flow cytometry to explore the effects of modulation of these genes on glioma. The results of this study suggested that m1A-RIGS may be an excellent prognostic indicator for patients with LGG, and could also promote development of novel immune-based treatment strategies for LGG. Additionally, BIRC5 and MSR1 may be potential therapeutic targets for LGG.